25.08.2010 • News

Air Products Files Hart-Scott-Rodino Notification for Acquisition of Airgas

Air Products today announced it has filed notification with the Federal Trade Commission (FTC) as required under the Hart-Scott-Rodino (HSR) Antitrust Improvement Act of 1976 for the acquisition of Airgas. The HSR waiting period will expire on Sept. 8 unless earlier terminated by the FTC.

On Aug. 16, Air Products announced it had reached an agreement with the staff of the FTC on the terms of a consent decree for the acquisition of Airgas. The consent decree would permit Air Products to acquire Airgas subject to the divestiture of certain assets and would also permit, for a period of time, the closing of the acquisition prior to completion of the divestiture.

The assets to be divested relate primarily to Airgas' liquid bulk and on-site supply of atmospheric gases, including production and related assets. Air Products has signed the consent decree, which is subject to review and approval by the commissioners of the FTC.

Upon termination of the HSR waiting period, Air Products will have satisfied the principal conditions to completing a transaction with Airgas, and there will remain no substantive impediments to closing immediately other than the intransigence of the Airgas Board.

The next step for Airgas shareholders to complete a transaction is to elect the three directors nominated by Air Products and approve its other proposals at the 2010 Airgas annual meeting on Sept. 15.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read